Image may be NSFW.
Clik here to view.
Ophthalmalogical-focused developer EyeGate Pharma said this week that the Phase 3 study of its EGP-437 delivered through its EyeGate II drug delivery system did not show non-inferiority to the prednisolone acetate ophthalmic solution control group.
The Phase 3 study was evaluating the safety and efficacy of the EGP-437 with the EyeGate II in patients with non-infectious anterior segment uveitis, the Waltham, Mass.-based company said.
Read the whole story on our sister site, Drug Delivery Business News
The post EyeGate’s Phase 3 EGP-437 study fails to show non-inferiority appeared first on MassDevice.
